Laurie Glimcher: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Line 12: Line 12:


==Work==
==Work==
Glimcher's research has focused on the [[immune system]]; she is known for early work with [[T cell]] differentiation, her discovery that [[HIVEP3|Schnurri-3]] regulates [[osteoblasts]] which led to a collaboration with [[Merck & Co.]], and her discovery of the role played by [[XBP1|XBP-1]] in [[lipogenesis]] and the [[unfolded protein response]].<ref>{{cite journal|last1=Neill|first1=US|title=A conversation with Laurie Glimcher.|journal=The Journal of clinical investigation|date=1 July 2016|volume=126|issue=7|pages=2392–3|pmid=27367182|pmc=4922720}}</ref><ref>{{Cite journal|last=Sedwick|first=Caitlin|date=2010-04-19|title=Laurie Glimcher: Merging cell biology and immune function|journal=The Journal of Cell Biology|volume=189|issue=2|pages=192–193|doi=10.1083/jcb.1892pi|pmid=20404104|pmc=2856904}}</ref> Her research has had implications for understanding [[asthma]], [[HIV]], [[inflammatory bowel disease]], and [[osteoporosis]], and around 2016, on [[cancer immunotherapy]].<ref>{{Cite web|url=https://www.statnews.com/2016/03/01/laurie-glimcher-dana-farber/|title=Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber|date=2016-03-01|website=STAT|access-date=2016-10-11}}</ref>
Glimcher's research has focused on the [[immune system]]; she is known for early work with [[T cell]] differentiation, her discovery that [[HIVEP3|Schnurri-3]] regulates [[osteoblasts]] which led to a collaboration with [[Merck & Co.]], and her discovery of the role played by [[XBP1|XBP-1]] in [[lipogenesis]] and the [[unfolded protein response]].<ref>{{cite journal|last1=Neill|first1=US|title=A conversation with Laurie Glimcher.|journal=The Journal of clinical investigation|date=1 July 2016|volume=126|issue=7|pages=2392–3|pmid=27367182|pmc=4922720}}</ref><ref>{{Cite journal|last=Sedwick|first=Caitlin|date=2010-04-19|title=Laurie Glimcher: Merging cell biology and immune function|journal=The Journal of Cell Biology|volume=189|issue=2|pages=192–193|doi=10.1083/jcb.1892pi|pmid=20404104|pmc=2856904}}</ref> Glimcher's role helped discover Schnurri-3 (Shn3 for short) is a large zinc finger protein distantly related to Drosophila. Shn is a potent and essential regulator of adult bone formation.<ref>{{Cite book|url=http://link.springer.com/chapter/10.1007/978-0-387-72009-8_1|title=Osteoimmunology|last=Jones|first=Dallas C.|last2=Wein|first2=Marc N.|last3=Glimcher|first3=Laurie H.|date=2007-01-01|publisher=Springer US|isbn=9780387720081|editor-last=Choi|editor-first=Yongwon|series=Advances in Experimental Medicine and Biology|pages=1–13|language=en|doi=10.1007/978-0-387-72009-8_1}}</ref> Her research has had implications for understanding [[asthma]], [[HIV]], [[inflammatory bowel disease]], and [[osteoporosis]], and around 2016, on [[cancer immunotherapy]].<ref>{{Cite web|url=https://www.statnews.com/2016/03/01/laurie-glimcher-dana-farber/|title=Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber|date=2016-03-01|website=STAT|access-date=2016-10-11}}</ref>


She joined the board of directors of [[Bristol-Myers Squibb]] in 1997.<ref name="nyt1">{{cite news|url=http://www.nytimes.com/2011/09/08/nyregion/laurie-h-glimcher-named-dean-of-weill-cornell-medical-college.html?_r=1|title=Harvard Researcher Chosen as New Dean of Weill Cornell Medical College|date=September 7, 2011|work=The New York Times|accessdate=September 9, 2011|author=Hartocollis, Anemona}}</ref><ref name="che1">{{cite news|url=http://chronicle.com/blogs/ticker/new-dean-of-weill-cornell-medical-college-calls-for-stronger-ties-to-industry/36049|title=New Dean of Weill Cornell Medical College Calls for Stronger Ties to Industry|date=September 8, 2011|work=Chronicle of Higher Education|accessdate=September 9, 2011}}</ref>
She joined the board of directors of [[Bristol-Myers Squibb]] in 1997.<ref name="nyt1">{{cite news|url=http://www.nytimes.com/2011/09/08/nyregion/laurie-h-glimcher-named-dean-of-weill-cornell-medical-college.html?_r=1|title=Harvard Researcher Chosen as New Dean of Weill Cornell Medical College|date=September 7, 2011|work=The New York Times|accessdate=September 9, 2011|author=Hartocollis, Anemona}}</ref><ref name="che1">{{cite news|url=http://chronicle.com/blogs/ticker/new-dean-of-weill-cornell-medical-college-calls-for-stronger-ties-to-industry/36049|title=New Dean of Weill Cornell Medical College Calls for Stronger Ties to Industry|date=September 8, 2011|work=Chronicle of Higher Education|accessdate=September 9, 2011}}</ref>

Revision as of 02:23, 10 December 2016

Laurie Glimcher
Born
Laurie Glimcher

1950
EducationRadcliffe College(1968-1972 B.A. 1972) Hardvard Medical School (1976)
Known forCancer Immunotherapy (research) Immune System (research) Osteoporosis (Clinical Specialty)

Laurie H. Glimcher is an American physician-scientist who was appointed President and CEO of Dana-Farber Cancer Institute in February 2016.[1] Laurie Glimcher is the daughter of Melvin Glimcher, who was a pioneer in the development in of artificial limbs while the chair of the Massachusetts General Hospital Orthopedics Department. Laurie Glimcher has been a pioneering force in the immerging field of osteoimmunology. She is a member of the National Academy of Sciences. She received the L'Oréal-UNESCO Awards for Women in Science in 2014.[2] Glimcher received her bachelor's degree at Radcliffe College in 1972 and her M.D. at Harvard Medical School in 1976.[3]

Work

Glimcher's research has focused on the immune system; she is known for early work with T cell differentiation, her discovery that Schnurri-3 regulates osteoblasts which led to a collaboration with Merck & Co., and her discovery of the role played by XBP-1 in lipogenesis and the unfolded protein response.[4][5] Glimcher's role helped discover Schnurri-3 (Shn3 for short) is a large zinc finger protein distantly related to Drosophila. Shn is a potent and essential regulator of adult bone formation.[6] Her research has had implications for understanding asthma, HIV, inflammatory bowel disease, and osteoporosis, and around 2016, on cancer immunotherapy.[7]

She joined the board of directors of Bristol-Myers Squibb in 1997.[8][9]

Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, a professor of medicine at Harvard Medical School.[10] Clinically, she is a specialist in osteoporosis.[8]

From 2012 to 2016 Glimcher served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College[11] and the Cornell University Provost for Medical Affairs.[12]

In February 2016, Laurie Glimcher was named the next president and CEO of Dana-Farber Cancer Institute. Glimcher was considered for the position for the Dean of Harvard Medical School but turned the position down in order to become the president of the Dana-Farber Cancer Institue.[13] The Dana-Farber Cancer Institue is an institution that is affiliated with Harvard, as it currently is one of it's teaching hospitals. Glimcher, who was the first female dean of any medical school in New York state, will become the first president to lead the Dana-Farber Cancer Institute.

Memberships[12]

Laurie Glimcher is a part of many different organizations and memberships. She is currently a part of:

  • American Academy of Arts and Sciences
  • American Association of Immunologist
  • American Society of Clincal Investigation
  • American Association of Physicians
  • American Association for the Advancement of Science

Women's involvement

Laurie Glimcher has been considered a champion of women's rights in the scientific by many of her peers. While she was at Harvard, Glimcher she hired lab techs with her own research money to support her postdoctoral fellows after they had babies so that they were allowed to leave by 6. This carried on into Glimcher's involvement with the National Institutes of Health to create a similar postdoc grant program caring for family members.[14]

Glimcher served on the 2005 Larry Summers Task Force for Women in Science and Engineering, where she expressed her disappointment in the rate of progress for women in science. She joined this task force after a controversy was sparked when former Harvard president Larry Summers suggested that women might be able to innately do less in science. Although she was on the Larry Summers committee, Glimcher still believes that there is still more work to be done. She was quoted as saying: "There are not enough women in senior leadership positions, period. It hasn't gotten a heck of a lot better since I was in medical school". After she was appointed to Cornell's medical school she immediately made changes regarding women's rights. She established paid maternity leave, created day car centers and another postdoc grant program for primary caregivers. Upon arriving at Cornell there were 0 out of 19 clincal ddepartmentchairs filled by women, as of today there are 2.

NYBC scandal

From October 2015 to February 2016, Glimcher was the target of eight protests by animal rights activists angered by New York Blood Center's abandonment of 66 chimpanzees that had been used in medical research; Glimcher was a member of the board of directors,[15] which had voted to stop paying for care of the chimpanzees before she joined it.[15][16][17] Glimcher said that the decision was made before her term on the board and said: "As a scientist, I strongly support the ethical and humane treatment of animals used in research.... I have a great respect for these animals and recognize the value they bring in our pursuit of new cures for devastating human diseases."[15]

References

  1. ^ "Laurie H. Glimcher, MD, named president of Dana-Farber Cancer Institute - Dana-Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved 2016-10-11.
  2. ^ 16th Annual L’ORÉAL-UNESCO Awards for Women in Science - 2014
  3. ^ "Gale Virtual Reference Library - Document - Glimcher, Laurie H". go.galegroup.com. Retrieved 2016-10-11.
  4. ^ Neill, US (1 July 2016). "A conversation with Laurie Glimcher". The Journal of clinical investigation. 126 (7): 2392–3. PMC 4922720. PMID 27367182.
  5. ^ Sedwick, Caitlin (2010-04-19). "Laurie Glimcher: Merging cell biology and immune function". The Journal of Cell Biology. 189 (2): 192–193. doi:10.1083/jcb.1892pi. PMC 2856904. PMID 20404104.
  6. ^ Jones, Dallas C.; Wein, Marc N.; Glimcher, Laurie H. (2007-01-01). Choi, Yongwon (ed.). Osteoimmunology. Advances in Experimental Medicine and Biology. Springer US. pp. 1–13. doi:10.1007/978-0-387-72009-8_1. ISBN 9780387720081.
  7. ^ "Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber". STAT. 2016-03-01. Retrieved 2016-10-11.
  8. ^ a b Hartocollis, Anemona (September 7, 2011). "Harvard Researcher Chosen as New Dean of Weill Cornell Medical College". The New York Times. Retrieved September 9, 2011.
  9. ^ "New Dean of Weill Cornell Medical College Calls for Stronger Ties to Industry". Chronicle of Higher Education. September 8, 2011. Retrieved September 9, 2011.
  10. ^ official p. at Harvard
  11. ^ Hartocollis, Anemona (2011-09-07). "Laurie H. Glimcher Named Dean of Weill Cornell Medical College". The New York Times. ISSN 0362-4331. Retrieved 2016-10-11.
  12. ^ a b "Bristol-Myers Squibb: Laurie H. Glimcher, M.D." www.bms.com. Retrieved 2016-12-08.
  13. ^ "Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber". STAT. 2016-03-01. Retrieved 2016-12-08.
  14. ^ "Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber". STAT. 2016-03-01. Retrieved 2016-12-09.
  15. ^ a b c "Weill Cornell Medicine Dean Accused of Chimp Abandonment". The Cornell Daily Sun. 2015-10-30. Retrieved 2016-10-11.
  16. ^ Gorman, James (28 May 2015). "Chimpanzees in Liberia, Used in New York Blood Center Research, Face Uncertain Future". The New York Times. Retrieved 12 November 2016.
  17. ^ Chimps in need after U.S. organization withdraws care - CNN.com

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Laurie_Glimcher&oldid=753968966"